Nasopharyngeal Neoplasms Clinical Trial
NCT number | NCT02444949 |
Other study ID # | CTGU001 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | June 2014 |
Est. completion date | December 2019 |
Verified date | June 2020 |
Source | China Three Gorges University, Yichang, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Among all the head and neck tumors, nasopharyngeal carcinoma (NPC) has a high tendency of recurrence and metastasis. For the advanced NPC patients, chemoradiotherapy is the main way of treatment. Currently, chemotherapy with cisplatin (DDP) combines with 5-fluorouracil (5-FU) is the classic front line therapy for NPC. However, the abnormal richness of angiogenesis of tumor and blood supply in tissue caused by radiation therapy often decrease the effects of radiochemotherapy. Human recombinant vascular endothelial inhibitor (endostar) can improve the sensitivity to chemoradiation via selectively inhibiting the migration of endothelial cells and the formation of tumor vessels. Moreover, it would induce vascular remodeling and normalization of the tumor vasculature, which will effectively aid the delivery of oxygen and anticancer drugs. In sum, antiangiogenesis in combination with chemoradiotherapy will be a promising way of treatment for NPC. In this study, the first-treated patients with NPC (stage Ⅲ or Ⅳa) confirmed by pathology, and patients with recurrent and metastatic NPC will be randomly assigned to two groups (1:1): a trial group (DDP, 5-FU, endostar and sequential intensity modulated radiation therapy (IMRT)), and a control group (DDP,5-FU and sequential IMRT). Evaluations will be developed including progression-free survival (PFS), Overall response rate(ORR), overall survival (OS), adverse effects rate and quality of life. This research will provide more evidences of evidence-based medicine for the safety and tolerability of endostar and the clinical application of endostar in NPC treatment.
Status | Completed |
Enrollment | 75 |
Est. completion date | December 2019 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Age from 18 to 70 ears ; - Eastern Cooperative Oncology Group performance status of 0-1; - diagnosed with first-treated NPC (?/?a stage) confirmed by pathology; - ecurrent and metastatic NPC with indication of chemoradiotherapy; - one measurable lesion at least (according to the RECIST guidelines, the lesion iameter=20 mm with MRI); - life expectancy of = 12 weeks; - adequate hematologic, renal, cardiac and liver function; - hemameba=4.0×109/L; - neutrophil=2.0×109/L; - platelet=100×109/L; - hemoglobin=95g/L; - Serum bilirubin, ALT and AST =1.5 times of maximum criteria; - sufficiently understand this study situation and signed the informed consent. Exclusion Criteria: - allergy or intolerance to study drugs; - receiving other anti-cancer therapy; - uncontrolled central nervous system lesions; - dysfunction of important organs; - history of cardiovascular disease(including congestive heart-failure, uncontrolled arrhythmia, angina pectoris which require long-term drug treatment, lular heart disease, myocardial infarction and resistant hypertension); - pregnancy or lactation in women; - protracted Infective wound; - history of mental illness which is not easy controlled. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
China Three Gorges University, Yichang, China |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival | Patients will be followed from the day in which patients are enrolled the clinical trial and end up one year later, during the one year the patients will be observed whether they have disease progress or die from any cause. | ||
Primary | Overall response rate | After the second periodicity chemotherapy, an expected average of 12 weeks, the rate of patients with complete response and partial response accounted for the total number of assessable cases . | ||
Secondary | Adverse effects as assessed by adverse events | It is the time from the start of treatment to 20 weeks | ||
Secondary | Overall survival | Patients will be followed from the day in which patients are enrolled the clinical trial and end up two years later, during the two years the patients will be observed whether they die from any cause. | ||
Secondary | Quality of Life measured by the ECDG score | Firstly, Patients will be assessed before the start of periodicity treatment, then they will be assessed 20 weeks and 24 weeks after the treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00577057 -
Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
|
N/A | |
Completed |
NCT01256853 -
Modified Vaccinia Ankara (MVA) Vaccine Study
|
Phase 1 | |
Recruiting |
NCT02945878 -
Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma
|
N/A | |
Terminated |
NCT02874651 -
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
|
Phase 2 | |
Not yet recruiting |
NCT05807880 -
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT00342147 -
Family Study of Head and Neck Cancers in Taiwan
|
||
Recruiting |
NCT02980315 -
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01735409 -
Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT00565448 -
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
|
Phase 2 | |
Completed |
NCT00630149 -
Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy
|
Phase 2 | |
Active, not recruiting |
NCT03854838 -
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
|
Phase 2 | |
Completed |
NCT01797900 -
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
|
Phase 2 | |
Completed |
NCT00436800 -
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT00563927 -
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
|
N/A | |
Not yet recruiting |
NCT04870905 -
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02902432 -
A Trial of Endostar in Patients With Carcinoma of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT02456506 -
Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.
|
N/A | |
Completed |
NCT00188877 -
Intensity Modulated Radiation Therapy for Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT00393224 -
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
|
||
Not yet recruiting |
NCT03093649 -
Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma
|
N/A |